178.62.71.222
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Geographic Atrophy

Study confirms safety of repeated 0.1-mL intravitreous injections on IOP in geographic atrophy

Posted on

In patients with geographic atrophy, repeated 0.1-mL intravitreous injections over 1 year are associated with a low risk of significant intraocular pressure (IOP) increases, suggesting that this injection volume is safe and does not lead to frequent IOP-related complications, according to results of a new post hoc analysis of 2 clinical trials

Participants, all aged 50 or older with bilateral geographic atrophy, were assigned to receive 0.1 mL of lampalizumab every 4 or 6 weeks, or a sham procedure, for 48 weeks.

The study included 1851 participants and found no change in mean pre-injection IOP values over the 48-week period across all study arms. Adverse events such as glaucoma and ocular hypertension were reported in 1.8% and 1.6% of participants treated with lampalizumab and sham, respectively.

The researchers concluded that “These results may be valuable in the design of future therapeutic trials considering this volume for injections particularly as more recently approved agents use volumes of 0.07 to 0.1 mL.”

Reference
Bressler NM, Freund KB, Bakri SJ, et al. Intraocular Pressure Outcomes After Lampalizumab Injections in Patients With Geographic Atrophy. JAMA Ophthalmol. 2024;e242061. doi: 10.1001/jamaophthalmol.2024.2061. Epub ahead of print. PMID: 38900484; PMCID: PMC11190824.

 

This content is independent editorial sponsored by Astellas. Astellas had no input in the development of this content.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-